A Study in Subjects With Retinitis Pigmentosa

An Open-label, Phase II Study of ADX-2191 in Subjects With Retinitis Pigmentosa

An open-label Phase II clinical trial, 8 (eight) subjects with retinitis pigmentosa due to rhodopsin mutations (including P23H) will be identified and treated with serial intravitreal injections of ADX-2191 in the worse seeing eye. Ocular structure and function will be evaluated.

Inclusion Criteria:

1. Up to 8 adult patients age 18 or older
2. Diagnosis of retinitis pigmentosa due to rhodopsin gene mutation, including P23H
3. Impairment on Visual Field as determined by perimetry

Exclusion Criteria:

1. Age < 18 years
2. Pregnant
3. Previous inflammatory/infectious events involving the eyes